Dr. Blessing Ogboo concentrates her practice on US and international patent preparation and prosecution with emphasis on drug-development and pharmaceutical based chemistries. Blessing has extensive experience with designing small molecule drugs, as well as a strong background in organic synthesis, biochemistry, structural biology and computational modeling.
Prior to joining the firm, Blessing worked as a Protein and Structural Chemistry Co-op at a leading pharmaceutical company where she provided technical knowledge in structural biology and structure-based drug design to cross-functional project teams.
While earning her PhD in Medicinal Chemistry at the State University of New York at Buffalo, Blessing also served as a graduate research and teaching assistant. In that role, she led cross-functional teams focused on improving mutant EGFR inhibitor potency. She also designed and synthesized NADPH oxidase 5 (NOX5)-selective inhibitors, while developing biochemical and cell-based assays to characterize these NOX5 inhibitors and EGFR PROTAC degraders for targeting lung cancer and inflammatory diseases.